News | September 10, 2025
Navin Fluorine inaugurates Phase-1 of new cGMP-4 facility of Navin Molecular at Devas
The cGMP-4 facility will further strengthen the company's ability to serve global partners
The cGMP-4 facility will further strengthen the company's ability to serve global partners
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Combination creates a leading, next generation claims operating system for payers, with end-to-end AI capabilities for claims, payments, care & utilization management, payment integrity, and member engagement, serving 115+ health plans
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
PendraCare Group develops, manufactures and sells innovative cardiology catheter solutions and provides design, development and manufacturing services to other global OEM’s
Subscribe To Our Newsletter & Stay Updated
